KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic

KisoJi Biotechnology Inc., a company focused on the discovery and development of transformative antibody therapeutics, announced that it has raised $41 million in equity, including the conversion of previously funded convertible debentures. These funds will be used to advance its lead asset, KJ-103, the first potent naked antibody against TROP2, into the clinic to treat solid tumours. Funds will also be used to deploy its cutting-edge antibody discovery platform towards new multi-specific therapeutic antibody drugs in cardiometabolic disease, as well as immunology and inflammation.

KisoJi Biotechnology presented at the OBIO® Investment Summit.